ROIV (STOCKS)
Roivant Sciences Ltd. Common Shares
$30.030000
-0.010000 (-0.03%)
Prev close: $30.040000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Matthew Gline
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $21,592.50M
- Employees
- 750
- P/E (TTM)
- -59.63
- P/B (TTM)
- 4.78
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q4)
|
$-0.58 | $-0.35 | -0.2277 | -64.63% |
|
Dec 2025 (Q3)
|
$-0.38 | $-0.32 | -0.0560 | -17.28% |
|
Sep 2025 (Q2)
|
$-0.17 | $-0.34 | +0.1710 | +50.15% |
|
Jun 2025 (Q1)
|
$-0.33 | $-0.32 | -0.0138 | -4.36% |
Financial Statements
| Revenues | $8.26M |
| Benefits Costs and Expenses | $272.84M |
| Costs And Expenses | $272.84M |
| Operating Expenses | $1.29B |
| Research and Development | $681.81M |
| Other Operating Expenses | $611.75M |
| Operating Income/Loss | -$515.07M |
| Income/Loss From Continuing Operations After Tax | -$397.91M |
| Income/Loss From Continuing Operations Before Tax | -$264.58M |
| Income/Loss From Discontinued Operations Net Of Tax | $0.00 |
| Income Tax Expense/Benefit | $133.33M |
| Income Tax Expense/Benefit, Current | $133.33M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$397.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$98.14M |
| Net Income/Loss Attributable To Parent | -$299.77M |
| Net Income/Loss Available To Common Stockholders, Basic | -$299.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.43 |
| Diluted Earnings Per Share | -$0.54 |
| Basic Average Shares | 693,864,530 |
| Diluted Average Shares | 693,864,530 |
| Assets | $5.71B |
| Current Assets | $5.17B |
| Cash | $4.30B |
| Other Current Assets | $867.38M |
| Noncurrent Assets | $541.30M |
| Fixed Assets | $11.99M |
| Other Non-current Assets | $529.32M |
| Liabilities | $416.28M |
| Current Liabilities | $281.24M |
| Accounts Payable | $18.00M |
| Wages | $87.33M |
| Other Current Liabilities | $175.92M |
| Noncurrent Liabilities | $135.03M |
| Equity | $5.29B |
| Equity Attributable To Noncontrolling Interest | $765.04M |
| Equity Attributable To Parent | $4.53B |
| Liabilities And Equity | $5.71B |
| Net Cash Flow From Operating Activities | -$750.35M |
| Net Cash Flow From Operating Activities, Continuing | -$750.35M |
| Net Cash Flow From Investing Activities | -$682.33M |
| Net Cash Flow From Investing Activities, Continuing | -$682.33M |
| Net Cash Flow From Financing Activities | $134.24M |
| Net Cash Flow From Financing Activities, Continuing | $134.24M |
| Net Cash Flow | -$1.30B |
| Net Cash Flow, Continuing | -$1.30B |
| Comprehensive Income/Loss | -$404.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$99.64M |
| Comprehensive Income/Loss Attributable To Parent | -$304.85M |
| Other Comprehensive Income/Loss | -$6.58M |